Clinical Trial Update: 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of BIIB074 (802NP302) for trigeminal neuralgia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trigeminal Neuralgia

Drugs mentioned

• BIIB074

Snippet

Sponsor: Biogen | Conditions: Trigeminal Neuralgia | Phase 3 | Status: WITHDRAWN